Tempering the Risk: Rift Valley Fever
Item Details
Title
Tempering the Risk: Rift Valley Fever
Topics
This article assesses the risk of Rift Valley Fever being used as a bioweapon and weighs it against the burden placed on research by its addition to the select agents list.
Date
2013
Conclusions
RVFV's addition to the select agents list has created a disincentive to study it as restrictions make it difficult. This delays progress in developing new vaccines and therapies. The largest risk of the disease is to livestock as it would not be an effective agent against humans due to low pathogenicity and transmissibility.
Source
Dar, O., Hogarth S., and McIntyre, S. Tempering the Risk: Rift Valley Fever and Bioterrorism. Tropical Medicine and International Health, Vol 18, No 8, August 2013. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169811/. Accessed March, 2024.
Citation
“Tempering the Risk: Rift Valley Fever,” Collection of Biothreat Risk Assessments (COBRA), accessed October 16, 2024, https://cobrabiosecurity.org/items/show/568.